Zobrazeno 1 - 10
of 19
pro vyhledávání: ''
Publikováno v:
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Background Delafloxacin is an oral or intravenous (IV) antibiotic indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI), including both gram-positive (including methicillin-resistant Staphylococcus aureus [MRSA])
Autor:
Per Dahlqvist, Kaja Grønning, Jeanette Wahlberg, Guri Grimnes, Bjørn G. Nedrebø, Jakob Skov, Åse Bjorvatn Sævik, Olle Kämpe, Synnove Emblem Holte, Anne Lise Dahle, Marcus Quinkler, Stina Therese Sollid, Marianne Øksnes, Eystein S. Husebye, Trine Finnes, Aneta Tomkowicz, Paal Methlie, Siri Carlsen, Anna-Karin Åkerman, Sophie Bensing, Charlotte Höybye, Katerina Simunkova, Ingrid Nermoen, Susanna Fonneland Valland, Anders Palmstrøm Jørgensen, Aleksandra Debowska
Publikováno v:
Journal of Clinical Endocrinology and Metabolism
2430–2441
The Journal of Clinical Endocrinology and Metabolism
2430–2441
The Journal of Clinical Endocrinology and Metabolism
Context Contrary to current dogma, growing evidence suggests that some patients with autoimmune Addison disease (AAD) produce corticosteroids even years after diagnosis. Objective To determine frequencies and clinical features of residual corticoster
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::abd6a8274469de94f8751253a4c18d8b
https://hdl.handle.net/10037/20133
https://hdl.handle.net/10037/20133
Autor:
Corrie, PG, Marshall, A, Nathan, PD, Lorigan, P, Gore, M, Tahir, S, Faust, G, Kelly, CG, Marples, M, Danson, SJ, Marshall, E, Houston, SJ, Board, RE, Waterston, AM, Nobes, JP, Harries, M, Kumar, S, Goodman, A, Dalgleish, A, Martin-Clavijo, A, Westwell, S, Casasola, R, Chao, D, Maraveyas, A, Patel, PM, Ottensmeier, CH, Farrugia, D, Humphreys, A, Eccles, B, Young, G, Barker, EO, Harman, C, Weiss, M, Myers, KA, Chhabra, A, Rodwell, SH, Dunn, JA, Middleton, MR, AVAST-M Investigators, Nathan, P, Dziewulski, P, Holikova, S, Panwar, U, Thomas, A, Corrie, P, Sirohi, B, Kelly, C, Middleton, M, Danson, S, Lester, J, Ajaz, M, Houston, S, Board, R, Eaton, D, Waterston, A, Nobes, J, Loo, S, Gray, G, Stubbings, H, Marsden, J, Patel, P, Ottensmeier, C, Dega, R, Herbert, C, Price, C, Brunt, M, Scott-Brown, M, Hamilton, J, Hayward, RL, Smyth, J, Woodings, P, Nayak, N, Burrows, L, Wolstenholme, V, Wagstaff, J, Nicolson, M, Wilson, A, Barlow, C, Scrase, C, Podd, T, Gonzalez, M, Stewart, J, Highley, M, Grumett, S, Talbot, T, Nathan, K, Coltart, R, Gee, B
Publikováno v:
Annals of Oncology
Corrie, P G, Marshall, A, Nathan, P D, Lorigan, P, Gore, M, Tahir, S, Faust, G, Kelly, C G, Marples, M, Danson, S J, Marshall, E, Houston, S J, Board, R E, Waterston, A M, Nobes, J P, Harries, M, Kumar, S, Goodman, A, Dalgleish, A, Martin-Clavijo, A, Westwell, S, Casasola, R, Chao, D, Maraveyas, A, Patel, P M, Ottensmeier, C H, Farrugia, D, Humphreys, A, Eccles, B, Young, G, Barker, E O, Harman, C, Weiss, M, Myers, K A, Chhabra, A, Rodwell, S H, Dunn, J A & Middleton, M R 2019, ' Adjuvant bevacizumab for melanoma patients at high risk of recurrence : survival analysis of the AVAST-M trial ', Annals of Oncology, vol. 30, no. 12, pp. 2013-2014 . https://doi.org/10.1093/annonc/mdz237
Corrie, P G, Marshall, A, Nathan, P D, Lorigan, P, Gore, M, Tahir, S, Faust, G, Kelly, C G, Marples, M, Danson, S J, Marshall, E, Houston, S J, Board, R E, Waterston, A M, Nobes, J P, Harries, M, Kumar, S, Goodman, A, Dalgleish, A, Martin-Clavijo, A, Westwell, S, Casasola, R, Chao, D, Maraveyas, A, Patel, P M, Ottensmeier, C H, Farrugia, D, Humphreys, A, Eccles, B, Young, G, Barker, E O, Harman, C, Weiss, M, Myers, K A, Chhabra, A, Rodwell, S H, Dunn, J A & Middleton, M R 2018, ' Adjuvant bevacizumab for melanoma patients at high risk of recurrence : survival analysis of the AVAST-M trial ', Ann Oncol., vol. 29, no. 8, pp. 1843-1852 . https://doi.org/10.1093/annonc/mdy229
Corrie, P G, Marshall, A, Nathan, P D, Lorigan, P, Gore, M, Tahir, S, Faust, G, Kelly, C G, Marples, M, Danson, S J, Marshall, E, Houston, S J, Board, R E, Waterston, A M, Nobes, J P, Harries, M, Kumar, S, Goodman, A, Dalgleish, A, Martin-Clavijo, A, Westwell, S, Casasola, R, Chao, D, Maraveyas, A, Patel, P M, Ottensmeier, C H, Farrugia, D, Humphreys, A, Eccles, B, Young, G, Barker, E O, Harman, C, Weiss, M, Myers, K A, Chhabra, A, Rodwell, S H, Dunn, J A & Middleton, M R 2019, ' Adjuvant bevacizumab for melanoma patients at high risk of recurrence : survival analysis of the AVAST-M trial ', Annals of Oncology, vol. 30, no. 12, pp. 2013-2014 . https://doi.org/10.1093/annonc/mdz237
Corrie, P G, Marshall, A, Nathan, P D, Lorigan, P, Gore, M, Tahir, S, Faust, G, Kelly, C G, Marples, M, Danson, S J, Marshall, E, Houston, S J, Board, R E, Waterston, A M, Nobes, J P, Harries, M, Kumar, S, Goodman, A, Dalgleish, A, Martin-Clavijo, A, Westwell, S, Casasola, R, Chao, D, Maraveyas, A, Patel, P M, Ottensmeier, C H, Farrugia, D, Humphreys, A, Eccles, B, Young, G, Barker, E O, Harman, C, Weiss, M, Myers, K A, Chhabra, A, Rodwell, S H, Dunn, J A & Middleton, M R 2018, ' Adjuvant bevacizumab for melanoma patients at high risk of recurrence : survival analysis of the AVAST-M trial ', Ann Oncol., vol. 29, no. 8, pp. 1843-1852 . https://doi.org/10.1093/annonc/mdy229
Background Bevacizumab is a recombinant humanised monoclonal antibody to vascular endothelial growth factor shown to improve survival in advanced solid cancers. We evaluated the role of adjuvant bevacizumab in melanoma patients at high risk of recurr
Autor:
Susumu Kodaira, Kazuaki Sasaki, Yoshiyuki Yamaguchi, Takayuki Morita, Genichi Nishimura, Sotaro Sadahiro, T. Tsuchiya, Seiji Sato, Hisashi Usuki, Junji Matsuoka, Keiji Koda, Chikuma Hamada, Kenji Katsumata, Ken Kondo, Yoshihiro Kakeji, Hideo Baba
Publikováno v:
Annals of Oncology
While adjuvant chemotherapy is preferable for colon cancer, treatment duration is controversial. This phase III trial is investigated optimal duration of adjuvant chemotherapy for Stage IIB/III colon cancer. Eighteen-month treatment with UFT/LV did n
Autor:
Christine E. MacBrayne, Sharon M Seifert, Peter L. Anderson, Marion G. Peters, Jose R Castillo-Mancilla, Diana M. Brainard, Raymond T. Chung, Arthur Y. Kim, Michael Hughes, Daniel S. Fierer, Kristen M. Marks, Susanna Naggie, Jennifer J. Kiser, Lane R. Bushman
BACKGROUND: The nucleotide analogues tenofovir and sofosbuvir are considered to have low potential for drug interactions. OBJECTIVES: To determine the effect of sofosbuvir-based HCV treatment on plasma concentrations of tenofovir and cellular concent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba94fda24efa618dc7f274ed8cc25ec4
https://europepmc.org/articles/PMC6054189/
https://europepmc.org/articles/PMC6054189/
Autor:
Jon Florholmen, Guro Forsdahl, Terkel Hansen, Rasmus Goll, Sandra Gouveia-Figueira, Rania Al-Mahdi, Einar Jensen, Joseph Diab, Thomas Moritz
Publikováno v:
Inflammatory Bowel Diseases
Background - The bioactive metabolites of omega 3 and omega 6 polyunsaturated fatty acids (ω-3 and ω-6) are known as oxylipins and endocannabinoids (eCBs). These lipid metabolites are involved in prompting and resolving the inflammatory response th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a38e87491875a20181f2cfcd0f162c1f
https://hdl.handle.net/10037/19447
https://hdl.handle.net/10037/19447
Autor:
Gavin J. Churchyard, Salome Charalambous, Lynn Morris, Andrew N. Phillips, Victoria Johnston, Lubbe Wiesner, Katherine Fielding, Alison D. Grant, Karen Cohen, Johanna Ledwaba
Publikováno v:
The Journal of Infectious Diseases
Background. High rates of second-line antiretroviral treatment (ART) failure are reported. The association with resistance and nonadherence on switching to second-line ART requires clarification. Methods. Using prospectively collected data from patie
Autor:
Christine Radebaugh, Michelle L. Ray, Jennifer J. Kiser, Lane R. Bushman, Craig W. Hendrix, Edward J. Fuchs, Mark S. Sulkowski, Adriana Andrade
OBJECTIVES The objective of this study was to evaluate the effects of abacavir on intracellular ribavirin triphosphate and plasma ribavirin trough concentrations. METHODS Hepatitis C virus-infected subjects who had been cured or failed prior treatmen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::73010f559eb81158e9add51ce26985d1
https://europepmc.org/articles/PMC4867100/
https://europepmc.org/articles/PMC4867100/
Publikováno v:
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Fidaxomicin has recently been approved for the treatment of Clostridium difficile infection (CDI). As part of phase III studies, plasma and fecal samples were analyzed for concentrations of fidaxomicin and its metabolite, OP-1118. Plasma samples were
Autor:
Michaela-Elena Friedrich, Dietmar Winkler, Anastasios Konstantinidis, Wolfgang Huf, Konstantinos Papageorgiou, Renate Grohmann, Siegfried Kasper, Waldemar Greil, Sermin Toto, Elena Akimova
Publikováno v:
International Journal of Neuropsychopharmacology
Background: Drug-induced liver injury is a common cause of liver damage and the most frequent reason for withdrawal of a drug in the United States. The symptoms of drug-induced liver damage are extremely diverse, with some patients remaining asymptom